Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TNXP Hot Sheet
Price: $7.30 +0.27%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Cantor Fitzgerald downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold with a price target of $1.00 (from $5.00).
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $0.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth
- Zeta Global Holdings Corp (ZETA) PT Raised to $38 at Truist Securities
- Sherwin-Williams (SHW) PT Lowered to $392 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
